Barbadin

Research use only, not for human use.

Barbadin is a novel and specific inhibitor of β-arrestin/β2-adaptin interaction with an IC50 value of 19.1 μM for β-arestin1 and 15.6 μM for β-arestin2.

Barbadin is a novel and selective β-arrestin/β2-adaptin interaction inhibitor, has IC50 values of 19.1 μM for β-arrestin1 and 15.6 μM for β-arrestin2. Barbadin blocks agonist-promoted endocytosis of the prototypical β2-adrenergic, V2-vasopressin and angiotensin-II type-1 receptors. Barbadin can induce apoptosis.

Barbadin (4 h) treatment reduces cell viability and induces apoptosis.?Barbadin (2 h) treatment arrests breast cancer cells in G0/G1 phase.Apoptosis Analysis Cell Line:MDA MB-231 cells Concentration:Incubation Time:4 hoursResult:Exhibited morphological characteristics of apoptosis including shrinkage, rounding and detachment, the percent of cell viability was reduced to 69.1% and apoptosis was developed in 29.9% of cells starved with EBSS (Earle’s balanced salt solution).Cell Cycle AnalysisCell Line:MDA MB-231 cells Concentration:Incubation Time:2 hours Result:Arrested 63.7% of cells in G0/G1 phase.

——

——

Others

Other Targets

Arrestin

——

——

356568-70-2

333.41

C19H15N3OS

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (149.97 mM; Ultrasonic )

Nn1cnc2scc(-c3ccc(Cc4ccccc4)cc3)c2c1=O

——

(-20℃)

With Ice Pack

≥ 2 years